Drug Trial Radar · NCT05800327
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
261
Planned (sponsor's estimate)
Start
Dec 7, 2022
Primary completion
Sep 2024
Study completion Dec 2027
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active rheumatoid arthritis resistant to methotrexate monotherapy. Aim of the Stage 1 is to study the tolerability, safety, immunogenicity, and main pharmacokinetic and pharmacodynamic parameters of levilimab after its single subcutaneous or intravenous administration at ascending doses to healthy subjects. Aim of the Stage 2 is to confirm the efficacy and safety of levilimab 648 mg IV Q4W in combination with methotrexate and levilimab 324 mg SC Q2W in combination with methotrexate in subjects with active rheumatoid arthritis, resistant to methotrexate monotherapy.
Conditions
- Rheumatoid Arthritis
Interventions
LevilimabDrug
Subcutaneous or intravenous injection of levilimab with placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety primary endpoint (Stage 1)Time frame: Up to day 71
- Low disease activity (Stage 2)Time frame: Up to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
X7 Clinical Research
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.